top of page

OMNIA team is happy to announce pre-clinical study results!

In November 2021 the OMNIA team started a preclinical

study phase with the T1DMS UVA/Padova simulator.

T1DMS is the first (and currently only) in a silico diabetes

model accepted by the FDA as a substitute for preclinical

treatment strategies for Type 1 Diabetes Mellitus. Adults group results: 90.27% TIR with 0.02 hypoglycemia! In June 2022, a pre-clinical results article was published

in one of one of the most authoritative diabetes journals

(Scopus Q1).

Read full article here:




bottom of page